Zevrix Releases Output Factory 1.1.5 for InDesign: Improves Output to Flash

Zevrix Solutions announces Output Factory 1.1.5, a maintenance update to its new solution to automate output from Adobe InDesign. Output Factory automates printing, exporting and post-processing from InDesign, and offers batch processing, single page export, variable file names, layer versioning, preflighting, processing history and more. The new version addresses some issues related to exporting to Flash as single files, as well as reliability issues of IDML and EPUB workflows.

Toronto (ON), Canada - April 3, 2012 -- Zevrix Solutions today announces the release of Output Factory 1.1.5, a maintenance update to its professional solution to automate printing, exporting and post-processing from Adobe InDesign. Output Factory is the major upgrade of the company's widely popular plug-in BatchOutput which automates and simplifies workflows of printers, prepress bureaus, design agencies and publishing houses worldwide.

The new version allows users to export InDesign documents to various Flash formats as single files. It also addresses some reliability issues of IDML and EPUB workflows on program's launch.

Output Factory is a powerful solution to automate InDesign's output tasks, whether users need to send hundreds of documents or just a single one. Users only need to select the files to output and adjust the settings, and Output Factory will do the rest automatically. For example, the software can be left exporting hundreds of InDesign files overnight, and the completed job can be picked up next morning.

"When every second counts Output Factory is a life saver!" says Glen Saville of the design firm glensaville.com in UK, "I had a 20 book job to do the other day and had to get PDFs out very quickly, and it was absolutely indispensable!"

Output Factory supports printing as well as exporting to PDF, PostScript, EPS, Flash, INX, IDML, EPUB and several image formats. It offers the following key features:

-Batch processing of InDesign files.

-Output as single pages.

-Save groups of output settings as workflows.

-Output to multiple workflows at once using actions.

-Update modified links automatically.

-Assign complex variable output file names.

-Layer versioning: output layer combinations as single files.

-Preflight documents using InDesign's preflight or built-in options.

-History: keep track of jobs, output files and errors.

Pricing and Availability:

Output Factory can be purchased from Zevrix website for US$169.95, as well as from authorized resellers. Trial is also available for download. Licensed BatchOutput users can upgrade to Output Factory for $84.97 ($40 for users who purchased BatchOutput after October 1, 2011). Output Factory is available for Mac OS X 10.5-10.7 on Intel-based Macs and works with Adobe InDesign CS3-CS5.5.

-Ends-

About Zevrix Solutions

Located in Toronto, Canada, Zevrix Solutions provides productivity solutions for Adobe Creative Suite software, PDF workflows, graphic file diagnostics, file delivery and Microsoft Office on Mac OS. Zevrix is dedicated to help professionals increase their profits through automating everyday tasks, producing error-free documents, saving disk space and cutting production costs. For more information, visit http://www.zevrix.com.

Contact:

Leo Revzin

Owner

Zevrix Solutions

105 McCAUL St, Suite 301

Toronto Ontario M5T 2X4 Canada

858-206-0607

media@zevrix.com

http://www.zevrix.com

Trials Show Promise of Human Virus to Treat Head and Neck Cancer Patients

Cancers shrank for about one third of the patients who could be evaluated, and disease stabilised for a further third. For one patient, all signs of their cancer disappeared.

Leeds, UK - April 3, 2012 -- A naturally-occurring harmless human virus may be able to boost the effects of two standard chemotherapy drugs in some cancer patients, according to early stage trial data published today in Clinical Cancer Research.

RT3D, trade name Reolysin, is a new drug developed by Oncolytics Biotech Inc with preclinical and clinical studies conducted at The Institute of Cancer Research (ICR) and The Royal Marsden Hospital. It is based on a virus (reovirus type 3 Dearing) that is found in almost all adults’ respiratory and gastrointestinal tracts without causing any symptoms.

RT3D has the ability to grow in and kill certain types of cancer cells, but does not grow in normal cells.

Previous trials injecting patients with the virus on its own showed limited effectiveness, but the team found that RT3D appeared to magnify the effects of platin and taxane-based chemotherapy on tumour cells.

Dr Kevin Harrington and colleagues in Leeds therefore started a clinical trial testing intravenous RT3D in combination with chemotherapeutics carboplatin and paclitaxel in 31 patients with advanced cancers who had stopped responding to standard treatments.

An initial Phase I study was carried out in patients with a range of advanced cancers, which showed the drug combination was safe. Side-effects were found to be generally mild, and consistent with chemotherapy alone.

Patients with head and neck cancers were found to have the best responses, so a Phase II expansion study at The Royal Marsden Hospital, London, and St James’s Hospital, Leeds, was therefore targeted to patients with these types of cancers.

Cancers shrank for about one third of the patients who could be evaluated, and disease stabilised for a further third. For one patient, all signs of their cancer disappeared.

“We saw really very impressive response rates in these patients. These are patients whose cancers had grown despite a great deal of previous treatment, including platinum-based chemotherapy for many,” Dr Harrington, Leader of the ICR’s Targeted Therapy Team and Consultant Oncologist at The Royal Marsden, said. “Under those circumstances, we'd expect that the average response rate to chemotherapy alone might be as low as single digits figures and the average survival would be somewhere between three to four months. In our Phase I/II study we show this had been prolonged to an average of seven months, albeit not in a randomised trial.”

“Based on the results of this study we've now started recruiting patients with advanced head and neck cancer to a randomised Phase III trial, in which all patients will receive chemotherapy and half will receive Reolysin as well. We are extremely excited about this progress.”

The study also found the virus was not shed after treatment. This means people could be given the drug as outpatients as no risk was found that they could transmit the virus to others.

Head and neck cancers include tumours of the eye, nasal cavity, tongue, gums, lip, cheeks, voice box and oesophagus. Around 650,000 people are diagnosed with squamous cell cancer of the head and neck each year worldwide, and around 350,000 die from the disease annually.

Notes to Editors:

Phase I/II trial of carboplatin and paclitaxel chemotherapy in combination with intravenous oncolytic reovirus in patients with advanced malignancies with first author Eleni M. Karapanagiotou from the ICR and The Royal Marsden publishes in the print edition of Clinical Cancer Research on April 1.

The Phase III trial is recruiting patients with head and neck cancer who have already been treated with platinum but not taxane. More details at: http://clinicaltrials.gov/ct2/show/NCT01166542

The Institute of Cancer Research (ICR) is one of the world’s most influential cancer research institutes.

Scientists and clinicians at the ICR are working every day to make a real impact on cancer patients’ lives. Through its unique partnership with The Royal Marsden Hospital and ‘bench-to-bedside’ approach, the ICR is able to create and deliver results in a way that other institutions cannot. Together the two organisations are rated in the top four cancer centres globally.

The ICR has an outstanding record of achievement dating back more than 100 years. It provided the first convincing evidence that DNA damage is the basic cause of cancer, laying the foundation for the now universally accepted idea that cancer is a genetic disease. Today it leads the world at isolating cancer-related genes and discovering new targeted drugs for personalised cancer treatment.

As a college of the University of London, the ICR provides postgraduate higher education of international distinction. It has charitable status and relies on support from partner organisations, charities and the general public.

The ICR’s mission is to make the discoveries that defeat cancer. For more information visit http://www.icr.ac.uk

The Royal Marsden NHS Foundation Trust

The Royal Marsden opened its doors in 1851 as the world’s first hospital dedicated to cancer diagnosis, treatment, research and education.

Today, together with its academic partner, The Institute of Cancer Research (ICR), it is the largest and most comprehensive cancer centre in Europe treating over 44,000 patients every year. It is a centre of excellence with an international reputation for groundbreaking research and pioneering the very latest in cancer treatments and technologies. The Royal Marsden also provides community services in the London boroughs of Sutton and Merton and in June 2010, along with the ICR, the Trust launched a new academic partnership with Mount Vernon Cancer Centre in Middlesex.

Since 2004, the hospital’s charity, The Royal Marsden Cancer Charity, has helped raise over £50 million to build theatres, diagnostic centres, and drug development units. Prince William became President of The Royal Marsden in 2007, following a long royal connection with the hospital.

Media Contacts:

Jane Bunce on 0207 153 5106 or after hours 077217 47900

Tatjana Trpoksa on 0207 153 5312 or after hours 07780689891

Media Contact (US) for Oncolytics: Janet Vasquez / 212-825-3210